Lutetium-177 dosimetry to predict response to PSMA radioligand therapy in metastatic prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, single-center study enrolling men with progressive metastatic prostate adenocarcinoma who are scheduled to receive 177Lu-PSMA radioligand therapy. Participants will undergo baseline PSMA PET/CT and dosimetry measurements during therapy to quantify the radiation dose delivered to tumors and normal tissues. Dosimetry results will be compared with biochemical (PSA) and imaging (PSMA PET/CT) responses after two treatment cycles and correlated with clinical outcomes including survival. The study aims to determine whether absorbed dose explains some cases of resistance and could inform future personalized dosing strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male aged ≥18 years with adenocarcinoma of the prostate.
* Progressive metastatic prostate cancer (progression defined as two consecutive increases of PSA, or progression by bone scan or by RECIST1.1).
* Candidate for 177Lu-PSMA-RLT, with at least one lesion showing significant PSMA uptake (uptake higher than liver physiologic activity).
* Able to start treatment within four weeks of baseline PSMA PET/CT.
* Willing and able to comply with all study requirements

Where it's running

• Institut Jules Bordet
  Brussels, Belgium Recruiting

Study contacts

• Study coordinator: Carlos Artigas, MD
• Email: carlos.artigas@hubruxelles.be
• Phone: 02.54137.81

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• Predicting prostate cancer response to neoadjuvant darolutamide with a gene biomarker

  This study tests whether a gene-based PCAI ImmunoScore can predict which high-risk localized or locally advanced prostate cancer patients will have minimal residual disease after 90–120 days of darolutamide before surgery.

  Recruiting at 2 sites Phase 2 Region Stockholm · Gothenburg and 1 other locations · NCT07617272

• Personal preferences for avoiding gynecomastia (Stage 1)

  This project will ask men with prostate cancer and high-risk biochemical recurrence what trade-offs they'd make to avoid breast-related side effects like gynecomastia.

  Recruiting St Vincent's Hospital, Sydney · Sydney, New South Wales · NCT07552922

• LaserSAFE: Quick in OR imaging to check margins during prostatectomy

  A new in‑the‑operating‑room imaging method called LaserSAFE is tested to see if it can quickly detect cancer at the edge of the prostate during surgery for patients undergoing robot-assisted prostatectomy.

  Recruiting University College, London · London · NCT07541911

• Early postoperative PSA after prostate removal as a predictor of cancer outcomes

  We will test whether early PSA levels after prostate removal can help predict long-term cancer outcomes in men undergoing radical prostatectomy.

  Recruiting Lithuanian University of Health Sciences · Kaunas, Kauno · NCT07516886

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.